PL4036099T3 - Sposoby wytwarzania rybozydów - Google Patents

Sposoby wytwarzania rybozydów

Info

Publication number
PL4036099T3
PL4036099T3 PL21209687.9T PL21209687T PL4036099T3 PL 4036099 T3 PL4036099 T3 PL 4036099T3 PL 21209687 T PL21209687 T PL 21209687T PL 4036099 T3 PL4036099 T3 PL 4036099T3
Authority
PL
Poland
Prior art keywords
ribosides
preparation
methods
Prior art date
Application number
PL21209687.9T
Other languages
English (en)
Inventor
Steven Donald Axt
Pavel Robertovich Badalov
Katrien Brak
Silvio Campagna
Andrei CHTCHEMELININE
Edward Doerffler
Morin Mae Frick
Detian GAO
Lars V. Heumann
Brittanie HOANG
Willard Lew
Robert Ronald Milburn
Sean Timothy Neville
Bruce Ross
Erick RUEDEN
Robert William Scott
Dustin Siegel
Andrew C. STEVENS
Clarissa TADEUS
Tiago VIERA
Andrew W. Waltman
Xianghong Wang
Mark Charles Whitcomb
Lydia WOLFE
Chia-Yun Yu
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54557474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4036099(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL4036099T3 publication Critical patent/PL4036099T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL21209687.9T 2014-10-29 2015-10-29 Sposoby wytwarzania rybozydów PL4036099T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072331P 2014-10-29 2014-10-29
US201562105619P 2015-01-20 2015-01-20

Publications (1)

Publication Number Publication Date
PL4036099T3 true PL4036099T3 (pl) 2025-06-23

Family

ID=54557474

Family Applications (5)

Application Number Title Priority Date Filing Date
PL20152978.1T PL3695844T3 (pl) 2014-10-29 2015-10-29 Remdesiwir, związek do zastosowania w leczeniu zakażeń wirusem nipah
PL21209687.9T PL4036099T3 (pl) 2014-10-29 2015-10-29 Sposoby wytwarzania rybozydów
PL18167340T PL3366295T3 (pl) 2014-10-29 2015-10-29 Sposoby leczenia zakażeń wirusem filoviridae
PL15797205T PL3212174T3 (pl) 2014-10-29 2015-10-29 Sposoby leczenia zakażeń wirusem filoviridae
PL15801008T PL3212175T3 (pl) 2014-10-29 2015-10-29 Sposoby wytwarzania rybozydów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20152978.1T PL3695844T3 (pl) 2014-10-29 2015-10-29 Remdesiwir, związek do zastosowania w leczeniu zakażeń wirusem nipah

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL18167340T PL3366295T3 (pl) 2014-10-29 2015-10-29 Sposoby leczenia zakażeń wirusem filoviridae
PL15797205T PL3212174T3 (pl) 2014-10-29 2015-10-29 Sposoby leczenia zakażeń wirusem filoviridae
PL15801008T PL3212175T3 (pl) 2014-10-29 2015-10-29 Sposoby wytwarzania rybozydów

Country Status (45)

Country Link
US (8) US11344565B2 (pl)
EP (7) EP3212174B1 (pl)
JP (9) JP6220484B1 (pl)
KR (6) KR20240125990A (pl)
CN (6) CN113620992B (pl)
AR (2) AR102467A1 (pl)
AU (8) AU2015339222B2 (pl)
BR (2) BR102015027413A2 (pl)
CA (3) CA3184285A1 (pl)
CL (2) CL2017001040A1 (pl)
CO (1) CO2017003960A2 (pl)
CR (2) CR20170483A (pl)
CU (2) CU20170145A7 (pl)
CY (2) CY1120893T1 (pl)
DK (2) DK3366295T3 (pl)
DO (1) DOP2017000103A (pl)
EA (2) EA201790630A1 (pl)
EC (2) ECSP17025261A (pl)
ES (5) ES3020561T3 (pl)
HR (1) HRP20181130T1 (pl)
HU (2) HUE039231T2 (pl)
IL (2) IL251560A0 (pl)
LT (2) LT3212174T (pl)
MA (3) MA40867A (pl)
MD (1) MD20170046A2 (pl)
ME (1) ME03070B (pl)
MX (3) MX2017005252A (pl)
MY (1) MY195823A (pl)
NZ (3) NZ730809A (pl)
PE (2) PE20180202A1 (pl)
PH (2) PH12017500631B1 (pl)
PL (5) PL3695844T3 (pl)
PT (4) PT3212175T (pl)
RS (1) RS57425B1 (pl)
SA (1) SA517381419B1 (pl)
SG (3) SG10202008772UA (pl)
SI (4) SI3212174T1 (pl)
SM (1) SMT201800381T1 (pl)
SV (2) SV2017005424A (pl)
TR (1) TR201809518T4 (pl)
TW (4) TWI767201B (pl)
UA (1) UA121485C2 (pl)
UY (2) UY36376A (pl)
WO (3) WO2016069827A1 (pl)
ZA (1) ZA201800414B (pl)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
WO2018089306A1 (en) * 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
US20190276481A1 (en) * 2016-11-18 2019-09-12 Neurovive Pharmaceutical Ab Liver Prodrugs of Mitochondrial Proton Ionophores
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
JP6923112B2 (ja) * 2017-03-31 2021-08-18 国立大学法人北海道大学 フィロウイルスの細胞侵入阻害活性を有するビアリールスルフォンアミド誘導体
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) * 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos
CN109535200A (zh) * 2017-09-21 2019-03-29 杭州和正医药有限公司 一种核苷类似物的磷酰胺酯前药、药物组合物及其应用
CN109748943A (zh) * 2017-11-03 2019-05-14 中国科学院上海药物研究所 2’-c-甲基取代核苷类化合物及其制备与用途
CN109748944B (zh) * 2017-11-03 2021-12-10 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN110330540A (zh) * 2019-08-08 2019-10-15 木天(济南)生物科技有限公司 核苷盐及其制备方法
CN110613726B (zh) * 2019-09-25 2020-10-16 广州六顺生物科技股份有限公司 核苷化合物的应用
WO2021095091A1 (ja) * 2019-11-11 2021-05-20 藤本化学製品株式会社 アミノアリール誘導体及びその中間体、並びにそれらの製造方法
CN110776512A (zh) * 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 一种核苷类似物的制备方法
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
CN113214263B (zh) * 2020-02-06 2022-09-30 北京桦冠医药科技有限公司 瑞德西韦关键中间体的一种合成方法
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN111205327B (zh) * 2020-02-17 2022-05-31 南京法恩化学有限公司 一种瑞德西韦的制备方法
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI884403B (zh) * 2020-02-18 2025-05-21 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
CN111171078B (zh) * 2020-02-27 2022-04-22 江苏阿尔法药业股份有限公司 一种瑞德西韦的合成方法
CN111205294B (zh) * 2020-02-27 2021-10-01 江苏阿尔法药业股份有限公司 一种瑞德西韦中间体的制备方法
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN111233930B (zh) * 2020-03-04 2022-05-13 江苏阿尔法药业股份有限公司 一种瑞德西韦的制备方法
CN113354699B (zh) * 2020-03-04 2023-07-18 中国科学院上海药物研究所 瑞德西韦的中间体及其制备方法
CN111269248A (zh) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 一种核苷氨基磷酸酯类药物母液回收的新方法
CN111269263A (zh) * 2020-03-09 2020-06-12 上海龙翔生物医药开发有限公司 一种瑞德西韦侧链中间体及其制备方法
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
CN111233869B (zh) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 用于制备瑞德西韦关键中间体的新化合物及其制备方法
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
JP2023518812A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
JP2023518814A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
CN111233931B (zh) * 2020-03-26 2022-03-22 宿迁盛基医药科技有限公司 一种瑞德西韦的合成方法
CN111398464B (zh) * 2020-04-02 2022-03-08 广州隽沐生物科技股份有限公司 2-乙基丁基（（全氟苯氧基）（苯氧基）磷酰基）-l-丙氨酸酯的检测方法
CN113493480B (zh) * 2020-04-03 2025-04-15 南京正大天晴制药有限公司 一种瑞德西韦异构体的制备及其分析方法
CN111423443A (zh) * 2020-04-03 2020-07-17 广州科锐特生物科技有限公司 一种4-氨基-7-碘吡咯并[2,1-f][1,2,4]三嗪的制备方法
WO2021207049A1 (en) * 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021207386A1 (en) * 2020-04-07 2021-10-14 Biocryst Pharmaceuticals, Inc. Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
CN113811309B (zh) * 2020-04-13 2023-05-05 山东华铂凯盛生物科技有限公司 用于治疗病毒感染的聚合物制剂及制备方法和用途
CN111393494A (zh) * 2020-04-17 2020-07-10 广东帕派恩生物科技有限公司 基于核苷酸结构的化合物、制备方法、用途
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN115605492B (zh) * 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
CN111471070B (zh) * 2020-04-26 2022-05-13 江苏阿尔法药业股份有限公司 瑞德西韦的合成方法
CN111454270B (zh) * 2020-04-27 2024-05-14 南通伟顺生物科技有限公司 一种含六元环的核苷类化合物及其制备方法
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
US10988503B1 (en) * 2020-05-06 2021-04-27 Nantong Weishun Biotechnology Co., Ltd Six-membered ring-containing nucleoside compound and preparation method thereof
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
RU2740660C1 (ru) * 2020-05-20 2021-01-19 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная композиция
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN111961057A (zh) * 2020-05-26 2020-11-20 李小冬 一种α构型核苷及其在治疗猫冠状病毒感染的应用
WO2021240543A1 (en) 2020-05-29 2021-12-02 Jubilant Generics Limited Transmucosal pharmaceutical compositions of antiviral drugs
IN202011022634A (pl) 2020-05-29 2020-10-09 Jubilant Generics Limited
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
CN113754693B (zh) * 2020-06-03 2022-09-09 上海交通大学 一种磷手性核苷衍生物的不对称催化合成方法及催化剂
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN113754694B (zh) * 2020-06-03 2022-10-25 上海交通大学 一种不对称催化无保护基核苷合成瑞德西韦的方法
WO2021257569A1 (en) * 2020-06-15 2021-12-23 Metro International Biotech, Llc Anti-viral compounds and methods of use
US12516081B2 (en) 2020-06-15 2026-01-06 Metro International Biotech, Llc Anti-viral compounds and methods of use
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
US20210393663A1 (en) * 2020-06-23 2021-12-23 Cai Gu Huang Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111961079A (zh) * 2020-07-17 2020-11-20 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和应用
MX2023001002A (es) 2020-07-24 2023-03-01 Univ California Farmacos antivirales, composiciones farmaceuticas, y metodos.
CA3185450A1 (en) 2020-08-06 2022-02-10 Istvan Borza Remdesivir intermediates
CN113004330A (zh) * 2020-08-22 2021-06-22 齐鲁制药有限公司 一种高纯度瑞德西韦的制备方法
AU2021330835B2 (en) 2020-08-24 2023-12-14 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
SI4204421T1 (sl) * 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
CN114105989A (zh) * 2020-08-31 2022-03-01 中国科学院大连化学物理研究所 一种碘代吡咯并三嗪胺类化合物的制备方法和应用
CN116685351A (zh) 2020-09-17 2023-09-01 基因泰克公司 Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究
CN112321642A (zh) * 2020-09-28 2021-02-05 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和用途
WO2022074630A1 (en) * 2020-10-09 2022-04-14 Auxilla Pharmaceuticals And Research Llp Liquid oral suspension of favipiravir
CN112194661B (zh) * 2020-10-22 2021-06-08 威海同丰海洋生物科技有限公司 一种4-氨基-7-碘吡咯并[2,l-f][l,2,4]三嗪的制备方法
EP4234557A4 (en) * 2020-10-26 2024-05-15 Vigonvita Life Sciences Co., Ltd. NUCLEOSIDE ANALOGUE SALT AND CRYSTALLINE FORM THEREOF, PHARMACEUTICAL COMPOSITION AND USE
CN114456212A (zh) * 2020-11-09 2022-05-10 广东东阳光药业有限公司 一种含磷化合物的制备方法
CN114507256B (zh) * 2020-11-16 2025-02-28 上海医药集团股份有限公司 一种瑞德西韦工艺手性异构体、其制备方法及其应用
RU2756921C1 (ru) * 2020-11-20 2021-10-07 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения ремдесивира и фосфорамидаты
BR112023009875A2 (pt) 2020-11-23 2024-02-06 Genentech Inc Métodos para tratar um indivíduo com uma infecção por sars-cov-2, para reduzir a ligação de sars-cov-2 a uma célula, para diminuir a infecção por sars-cov-2 e para identificar um modulador, métodos de profilaxia, moduladores isolados, usos e antagonistas
CN112358513A (zh) * 2020-12-02 2021-02-12 上海朴颐化学科技有限公司 一种利用连续流反应器制备瑞德西韦中间体的方法
CN114621229B (zh) * 2020-12-11 2024-07-02 嘉兴金派特生物科技有限公司 治疗或预防猫传染性腹膜炎的化合物或组合物
CN114644666B (zh) * 2020-12-18 2026-03-03 上海特化医药科技有限公司 5’-核苷前药的制备方法及中间体
CN114685511A (zh) * 2020-12-25 2022-07-01 上海科胜药物研发有限公司 一种瑞德西韦中间体的纯化方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN113754665B (zh) * 2020-12-30 2022-08-19 南方科技大学 一种核苷类化合物的制备方法
JP2024503755A (ja) * 2020-12-30 2024-01-26 サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー ウイルス感染症治療用ヌクレオシド系化合物及びその用途
US12558364B2 (en) 2021-01-20 2026-02-24 Regents Of The University Of Minnesota Next generation remdesivir antivirals
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
WO2022166581A1 (zh) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN117157081A (zh) * 2021-02-19 2023-12-01 南京赛弗斯医药科技有限公司 一种具有抗肿瘤活性的核苷酸衍生物及其药物组合物和用途
CN112979736B (zh) * 2021-03-04 2022-03-25 南京欧信医药技术有限公司 一种瑞德西韦的制备方法
CN115109077A (zh) * 2021-03-18 2022-09-27 上海医药集团股份有限公司 瑞德西韦中间体的制备方法
EP4323361A1 (en) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
EP4346772B1 (en) 2021-05-26 2026-04-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
CN113683640B (zh) * 2021-08-10 2025-01-14 浙江华海药业股份有限公司 一种丁基瑞德西韦的制备方法
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
CN113999237B (zh) * 2021-10-29 2023-08-08 润佳（苏州）医药科技有限公司 一种核苷类前药及其用途
KR102675967B1 (ko) 2021-11-02 2024-06-17 충남대학교산학협력단 렘데시비르를 함유하는 나노지질담체, 이의 제조방법 및 이를 포함하는 약학적 조성물
CN114409655A (zh) * 2022-01-26 2022-04-29 郑州大学 3′,4′-不饱和核糖c-核苷类似物及其制备方法
CN118591377A (zh) 2022-01-26 2024-09-03 加利福尼亚大学董事会 抗病毒前药、中效和长效制剂和方法
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
CN115028672A (zh) * 2022-06-14 2022-09-09 南京正济医药研究有限公司 瑞德西韦中间体晶体及其制备方法
CN116874491A (zh) * 2022-07-12 2023-10-13 深圳安泰维生物医药有限公司 一种n-保护的吡咯并三嗪碳苷类化合物及其制备方法
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
EP4619003A1 (en) 2022-11-18 2025-09-24 Gilead Sciences, Inc. Methods for treating poxvirus infections
CN115737675B (zh) * 2022-11-28 2024-03-08 安徽农业大学 氧化型硒代硫酸钠的制备及其在治疗冠状病毒感染中的应用
CN115947759A (zh) * 2022-12-13 2023-04-11 安徽大学 一种治疗新冠药物瑞德西韦的制备方法
CN116284135B (zh) * 2023-05-04 2025-03-21 南京颐媛生物医学研究院有限公司 抗冠状病毒核苷类化合物的制备方法及其应用
CN116332996B (zh) * 2023-05-04 2025-04-01 南京颐媛生物医学研究院有限公司 L-呋喃核糖型抗冠状病毒化合物及其制备方法和应用
HUP2300153A1 (hu) 2023-05-09 2024-11-28 Rotachrom Tech Zrt Eljárás remdesivir foszfor sztereoizomereinek elválasztására akirális folyadék-folyadék kromatográfiával
CN116554176A (zh) * 2023-05-11 2023-08-08 南京正济医药研究有限公司 一种核苷类化合物的制备方法
CN117126199B (zh) * 2023-05-17 2024-12-06 江西师范大学 一种氟代瑞德西韦合成方法
CN117343114A (zh) * 2023-09-22 2024-01-05 山东大学 一种高立体选择性的α-木糖吡喃糖苷键构建方法
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN117800872A (zh) * 2023-12-25 2024-04-02 海门瑞一医药科技有限公司 一种4-羟基丁腈的合成方法

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
JPH1017629A (ja) 1996-07-04 1998-01-20 Kayaku Akzo Kk ハードコート用樹脂組成物及びその硬化方法
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
AU3247899A (en) 1998-03-03 1999-09-20 Novo Nordisk A/S New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2326535A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
CA2346289A1 (en) 1998-10-16 2000-04-27 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for gaba receptors
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
JP4768132B2 (ja) * 1999-03-24 2011-09-07 エクシコン エ／エス ［２．２．１］ビシクロヌクレオシドの改良された製法
CA2376016A1 (en) * 1999-06-03 2000-12-14 Abbott Laboratories Oligonucleotide synthesis with lewis acids as activators
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
AU7490600A (en) 1999-09-15 2001-04-17 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
CZ304734B6 (cs) 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10145223A1 (de) 2001-09-13 2003-04-03 Basf Ag Verfahren zur Herstellung von meso-Zeaxanthin
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20050250728A1 (en) 2002-05-23 2005-11-10 Shanta Bantia Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
EP2359833A1 (en) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP2617709B8 (en) 2003-06-26 2022-12-21 Biotron Limited Guanidine derivatives as antiviral agents
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
CN1863813B (zh) 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
JP2005187428A (ja) * 2003-12-26 2005-07-14 Univ Of Tokyo 抗ｍｇｌ抗体によるフィロウイルス治療薬
JP2005185235A (ja) * 2003-12-26 2005-07-14 Univ Of Tokyo ウイルス感染に対する感受性診断のための方法およびキット。
ATE557013T1 (de) 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101043893A (zh) 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CA2584367A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
JP5089395B2 (ja) 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
CA2587639A1 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
EP1863500A2 (en) 2005-03-29 2007-12-12 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
AR056327A1 (es) 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
NZ596107A (en) 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
ES2436404T3 (es) 2005-10-03 2013-12-30 University Health Network Inhibidores ODCasa para el tratamiento de malaria
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EP1954264B1 (en) 2005-12-01 2009-10-07 Basilea Pharmaceutica AG Process for the manufacture of epoxybutanol intermediates
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
MY150667A (en) 2005-12-09 2014-02-28 Gilead Pharmasset Llc Antiviral nucleosides
JP5112328B2 (ja) 2005-12-09 2013-01-09 バジリア ファルマスーチカ アーゲー 重度の皮膚科障害の局所的処置のための４−オキソ（イソ）トレチノイン
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
DE102006015378A1 (de) 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Verfahren zur Synthese von Organoelementverbindungen
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
AR063569A1 (es) * 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
WO2008079206A1 (en) 2006-12-20 2008-07-03 Merck & Co., Inc. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
SI2114980T1 (sl) * 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2685520A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
ES2563477T3 (es) 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
KR101502533B1 (ko) 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
ES2398684T3 (es) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
NZ594370A (en) * 2009-02-10 2014-01-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
AU2010226466A1 (en) 2009-03-20 2011-10-20 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
KR101763672B1 (ko) 2009-03-24 2017-08-01 바이오크리스트파마슈티컬즈,인코포레이티드 7―［（3ｒ,4ｒ）―3―하이드록시―4―하이드록시메틸―피롤리딘―1―일메틸］―3,5―디하이드로―피롤로［3,2―ｄ］피리미딘―4―온의 유용한 약학적 염
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011011303A1 (en) 2009-07-21 2011-01-27 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
TWI483950B (zh) * 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
PE20120995A1 (es) 2009-09-21 2012-08-01 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2519102B1 (en) 2009-12-28 2016-10-19 Development Center For Biotechnology NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
KR101995598B1 (ko) * 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之２’－氟取代之碳－核苷類似物
PE20171624A1 (es) 2010-09-20 2017-11-02 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
PL2898885T3 (pl) 2010-10-15 2018-04-30 Biocryst Pharmaceuticals, Inc. Pochodne pirolopirymidynowe do zastosowania w leczeniu zakażeń wirusowych
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
EA201391264A1 (ru) 2011-04-13 2014-03-31 Джилид Сайэнс, Инк. 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
KR20200040899A (ko) 2011-05-13 2020-04-20 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
EP3384938A1 (en) * 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013084165A1 (en) * 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
EP2794630A4 (en) * 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
EP2890704B1 (en) 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
MX2015002954A (es) 2012-09-10 2015-06-05 Hoffmann La Roche Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
WO2014042433A2 (en) * 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
WO2014078778A2 (en) 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
CA2891125A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
GEP201706757B (en) * 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2014116755A1 (en) 2013-01-22 2014-07-31 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US9542154B2 (en) 2013-06-25 2017-01-10 Intel Corporation Fused multiply add operations using bit masks
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
DK3043865T3 (da) 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EA201691261A1 (ru) 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
JP6306750B2 (ja) 2014-03-07 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン
RU2016146365A (ru) 2014-05-13 2018-06-19 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
US9616076B2 (en) * 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
WO2016107832A1 (en) 2014-12-30 2016-07-07 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
EP3240913A1 (en) 2014-12-31 2017-11-08 F. Hoffmann-La Roche AG A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
CN107207505B (zh) 2015-02-11 2018-12-14 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
SG11201907034PA (en) 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CN111265532A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
JP7554841B2 (ja) * 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法

Also Published As

Publication number Publication date
MX378299B (es) 2025-03-10
TW201629076A (zh) 2016-08-16
JP6220484B1 (ja) 2017-10-25
JP6671424B2 (ja) 2020-03-25
UY36376A (es) 2016-06-01
CY1120893T1 (el) 2020-05-29
CA2963907A1 (en) 2016-05-06
LT3366295T (lt) 2020-04-27
JP2019048901A (ja) 2019-03-28
MX2017005250A (es) 2017-07-26
PT3212175T (pt) 2022-01-25
HK1258795A1 (en) 2019-11-22
EP4588928A2 (en) 2025-07-23
CN114191438A (zh) 2022-03-18
PT3366295T (pt) 2020-04-21
KR102337664B1 (ko) 2021-12-10
AR102468A1 (es) 2017-03-01
SG11201702904RA (en) 2017-05-30
HUE049192T2 (hu) 2020-09-28
US20200197422A1 (en) 2020-06-25
EP3366295B1 (en) 2020-01-22
ES3026734T3 (en) 2025-06-12
NZ745328A (en) 2023-06-30
PE20171439A1 (es) 2017-09-29
SA517381419B1 (ar) 2022-07-07
HRP20181130T1 (hr) 2018-09-21
AU2021201474B2 (en) 2023-02-02
JP2017534614A (ja) 2017-11-24
DOP2017000103A (es) 2017-05-15
EP3212174A1 (en) 2017-09-06
ES2785034T3 (es) 2020-10-05
SI3212174T1 (en) 2018-06-29
JP2020097635A (ja) 2020-06-25
JP2022065066A (ja) 2022-04-26
SV2017005424A (es) 2018-07-18
MA52506A (fr) 2021-03-10
TWI740546B (zh) 2021-09-21
AU2015339223A1 (en) 2017-04-27
CN113620992A (zh) 2021-11-09
KR102453808B1 (ko) 2022-10-12
PT3212174T (pt) 2018-06-28
AU2022283772A1 (en) 2023-02-02
CA2963832A1 (en) 2016-05-06
EP4588928A3 (en) 2025-09-24
HUE039231T2 (hu) 2018-12-28
PH12020551055A1 (en) 2021-07-26
CA3184285A1 (en) 2016-05-06
KR20220140656A (ko) 2022-10-18
NZ730803A (en) 2018-09-28
ES2904298T3 (es) 2022-04-04
ECSP17072474A (es) 2017-12-01
CR20170165A (es) 2017-06-19
AU2015339222A1 (en) 2017-04-27
CN113620992B (zh) 2024-09-03
EA201790630A1 (ru) 2017-11-30
EP4591935A3 (en) 2026-03-04
AR102467A1 (es) 2017-03-01
JP7158428B2 (ja) 2022-10-21
LT3212174T (lt) 2018-07-10
SG11201702903TA (en) 2017-05-30
TR201809518T4 (tr) 2018-07-23
US20210052613A1 (en) 2021-02-25
US20160361330A1 (en) 2016-12-15
TWI698444B (zh) 2020-07-11
ES3020561T3 (en) 2025-05-23
CN107073005A (zh) 2017-08-18
EA201790597A1 (ru) 2017-11-30
IL251707A0 (en) 2017-06-29
JP2017533903A (ja) 2017-11-16
DK3212174T3 (en) 2018-08-06
CR20170483A (es) 2018-01-22
KR20170067898A (ko) 2017-06-16
KR20210152015A (ko) 2021-12-14
WO2016069827A1 (en) 2016-05-06
US20190275063A1 (en) 2019-09-12
CY1122946T1 (el) 2021-10-29
AU2018253483A1 (en) 2018-11-15
EP3212175B1 (en) 2021-11-24
NZ730809A (en) 2018-09-28
PL3212175T3 (pl) 2022-02-28
EP3695844A1 (en) 2020-08-19
KR20240125990A (ko) 2024-08-20
DK3366295T3 (da) 2020-04-06
CN113549120B (zh) 2025-04-29
UA121485C2 (uk) 2020-06-10
PL3366295T3 (pl) 2020-08-24
ES2674806T3 (es) 2018-07-04
MD20170046A2 (ro) 2017-10-31
US20220354873A1 (en) 2022-11-10
CN107073005B (zh) 2021-12-24
PT3695844T (pt) 2025-05-29
AU2018253483B2 (en) 2020-04-16
TWI687432B (zh) 2020-03-11
EP3212174B1 (en) 2018-05-16
BR112017007636A2 (pt) 2017-12-19
EP3695844B1 (en) 2025-04-02
AU2015339222B2 (en) 2018-11-22
KR101822348B1 (ko) 2018-01-25
US11344565B2 (en) 2022-05-31
WO2016069826A1 (en) 2016-05-06
KR20170077167A (ko) 2017-07-05
AU2015339223B2 (en) 2018-07-26
TWI767201B (zh) 2022-06-11
AU2019201232A1 (en) 2019-03-14
PL3212174T3 (pl) 2018-09-28
US9724360B2 (en) 2017-08-08
TW202115098A (zh) 2021-04-16
AU2021201474A1 (en) 2021-03-25
MA40872A (fr) 2021-05-26
EP3212175A1 (en) 2017-09-06
SI3695844T1 (sl) 2025-06-30
PL3695844T3 (pl) 2025-07-21
CN118812607A (zh) 2024-10-22
CO2017003960A2 (es) 2017-07-11
IL251560A0 (en) 2017-05-29
EP4036099C0 (en) 2025-03-19
MA40867A (fr) 2017-09-06
JP2018172424A (ja) 2018-11-08
EP4591935A2 (en) 2025-07-30
JP6757294B2 (ja) 2020-09-16
CL2017002693A1 (es) 2018-04-20
CU20170145A7 (es) 2018-07-05
CA2963832C (en) 2020-06-16
CU20170056A7 (es) 2017-07-04
AU2020203892A1 (en) 2020-07-02
TW201630925A (zh) 2016-09-01
JP6487547B2 (ja) 2019-03-20
IL251707B (en) 2019-12-31
CN113549120A (zh) 2021-10-26
PH12017500631B1 (en) 2024-01-05
MY195823A (en) 2023-02-22
EA032239B1 (ru) 2019-04-30
ME03070B (me) 2019-01-20
BR102015027413A2 (pt) 2016-05-03
MX2020012560A (es) 2021-02-09
SI3212175T1 (sl) 2022-01-31
EP4036099A1 (en) 2022-08-03
US9949994B2 (en) 2018-04-24
RS57425B1 (sr) 2018-09-28
PE20180202A1 (es) 2018-01-31
JP2022068297A (ja) 2022-05-09
WO2016069825A1 (en) 2016-05-06
KR102694960B1 (ko) 2024-08-14
CN107074902A (zh) 2017-08-18
CL2017001040A1 (es) 2018-01-19
US20160122356A1 (en) 2016-05-05
SMT201800381T1 (it) 2018-09-13
JP2020090536A (ja) 2020-06-11
JP2017186358A (ja) 2017-10-12
ZA201800414B (en) 2019-10-30
SI3366295T1 (sl) 2020-06-30
US11266666B2 (en) 2022-03-08
US20160122374A1 (en) 2016-05-05
TW202039526A (zh) 2020-11-01
EP4036099B1 (en) 2025-03-19
EP3366295A1 (en) 2018-08-29
CA2963907C (en) 2023-04-04
US20180311263A1 (en) 2018-11-01
UY37464A (es) 2019-04-30
US10251898B2 (en) 2019-04-09
AU2019201232B2 (en) 2020-12-10
AU2023202679A1 (en) 2023-05-18
PH12017500631A1 (en) 2017-09-25
US10695357B2 (en) 2020-06-30
ECSP17025261A (es) 2017-05-31
MX2017005252A (es) 2017-07-26
SG10202008772UA (en) 2020-10-29
SV2017005561A (es) 2018-12-05
KR20170066665A (ko) 2017-06-14

Similar Documents

Publication Publication Date Title
IL251560A0 (en) Methods for preparing ribosides
GB201416842D0 (en) Aircraft
GB201405553D0 (en) Rotor-Lift Aircraft
PL3177817T3 (pl) Statek powietrzny
GB201508950D0 (en) Methods
GB201413086D0 (en) Methods
ZA201706795B (en) Process for the preparation of dicycloplatin
IL248267A0 (en) A process for preparing converted cycloserines
GB201518762D0 (en) Methods
GB201508927D0 (en) Methods
GB201408745D0 (en) Methods
IL247443B (en) Process for the preparation of 5-fluorotryptophol
GB201515655D0 (en) Methods
IL249130B (en) Preparation of piperidine-4-carbothioamide
ZA201701973B (en) Process for the preparation of halo-substituted trifluoroacetophenones
IL241974A0 (en) Process for making erlotinib
HUE043114T2 (hu) Eljárás tetrakonazol elõállítására
GB201512609D0 (en) Methods
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására
GB201415685D0 (en) Methods
GB201410184D0 (en) Odontalgic preparation
GB201507279D0 (en) Odontalgic preparation
GB201510756D0 (en) Methods
GB201509909D0 (en) Methods
GB201509813D0 (en) Methods